Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development...
$6.8M CARB-X award plus $6.4M Series B led by Omnimed will help bring new technology to the fight against drug resistance. AUSTIN, Texas, February 4, 2020 – Pattern Bioscience, Inc., formerly operating as Klaris Diagnostics, today announced $13M in funding for the...
Klaris has been selected as a finalist in the AMR Diagnostics Challenge federal prize competition, and will receive $100,000 to further develop its rapid ID/AST technology. The Challenge is a joint effort between the National Institutes of Health and the HHS Office...
Series A Financing Led by Omnimed Capital Austin, Texas, May 17, 2018 – Klaris Diagnostics, an in vitro diagnostics company focused on simplifying antibiotic selection for drug-resistant infections, today announced the completion of a $3.75 million Series...
